Terms: = Sarcomas AND NDRG1, NDR1, 10397, ENSG00000104419, Q92597, RIT42, CMT4D, TARG1, HMSNL, GC4, RTP, TDD5, PROXY1, NMSL, CAP43 AND Treatment
6 results:
1. ndrg1 regulates osteosarcoma cells via mediating the mitochondrial function and CSCs differentiation.
Zhao T; Meng Y; Wang Y; Wang W
J Orthop Surg Res; 2021 Jun; 16(1):364. PubMed ID: 34099022
[TBL] [Abstract] [Full Text] [Related]
2. HER4 promotes cell survival and chemoresistance in osteosarcoma via interaction with ndrg1.
Wang H; Sun W; Sun M; Fu Z; Zhou C; Wang C; Zuo D; Zhou Z; Wang G; Zhang T; Xu J; Chen J; Wang Z; Yin F; Duan Z; Hornicek FJ; Cai Z; Hua Y
Biochim Biophys Acta Mol Basis Dis; 2018 May; 1864(5 Pt A):1839-1849. PubMed ID: 29524631
[TBL] [Abstract] [Full Text] [Related]
3. ndrg1 inhibition sensitizes osteosarcoma cells to combretastatin A-4 through targeting autophagy.
Wang H; Li W; Xu J; Zhang T; Zuo D; Zhou Z; Lin B; Wang G; Wang Z; Sun W; Sun M; Chang S; Cai Z; Hua Y
Cell Death Dis; 2017 Sep; 8(9):e3048. PubMed ID: 28906492
[TBL] [Abstract] [Full Text] [Related]
4. Effects of long-term low oxygen tension in human chondrosarcoma cells.
Piltti J; Bygdell J; Qu C; Lammi MJ
J Cell Biochem; 2018 Feb; 119(2):2320-2332. PubMed ID: 28865129
[TBL] [Abstract] [Full Text] [Related]
5. Comprehensive MRI simulation methodology using a dedicated MRI scanner in radiation oncology for external beam radiation treatment planning.
Paulson ES; Erickson B; Schultz C; Allen Li X
Med Phys; 2015 Jan; 42(1):28-39. PubMed ID: 25563245
[TBL] [Abstract] [Full Text] [Related]
6. MLN0128, an ATP-competitive mTOR kinase inhibitor with potent in vitro and in vivo antitumor activity, as potential therapy for bone and soft-tissue sarcoma.
Slotkin EK; Patwardhan PP; Vasudeva SD; de Stanchina E; Tap WD; Schwartz GK
Mol Cancer Ther; 2015 Feb; 14(2):395-406. PubMed ID: 25519700
[TBL] [Abstract] [Full Text] [Related]
